LOTRIMIN AF (Tolnaftate 1%) DAILY PREVENTION deodorant powder spray, NET WT 160g (5.6 OZ) can, UP...

FDA Drug Recall #D-0254-2022 — Class II — October 1, 2021

Recall Summary

Recall Number D-0254-2022
Classification Class II — Moderate risk
Date Initiated October 1, 2021
Status Terminated
Voluntary Voluntary: Firm initiated

Recalling Firm

Firm Bayer Healthcare Pharmaceuticals Inc.
Location Whippany, NJ
Product Type Drugs
Quantity 579,456 units

Product Description

LOTRIMIN AF (Tolnaftate 1%) DAILY PREVENTION deodorant powder spray, NET WT 160g (5.6 OZ) can, UPC 0 41100 58720 6, NDC 11523-0010-2; Dist by: Bayer Healthcare LLC, Whippany, NJ 07981, Product of Finland, Packaged with LOTRIMIN ULTRA (butenafine hydrochloride 1%) cream, UPC 0 11017 40823 9, Dist by: Bayer Healthcare LLC, Whippany, NJ 07981, Product of Japan, ECOM PK UPC 00041100590756 NDC 11523-0010-2

Reason for Recall

cGMP Deviations: LOTRIMIN AF (Tolnaftate 1%) manufactured at the same facility where other lots were found to be contaminated with benzene.

Distribution Pattern

Distributed Nationwide in the US, Puerto Rico, Canada and Mexico through a variety of retail channels.

Lot / Code Information

Lot # NAA8997, EXP 01/31/2022; NAA8EK8, EXP 02/28/2022; NAA9E18, NAA9LFP, NAA9T53, NAA5RW, EXP 08/31/2022;

Other Recalls from Bayer Healthcare Pharmaceuticals Inc.

Recall # Classification Product Date
D-0145-2024 Class I VITRAKVI (larotractenib) oral solution, 20mg/mL... Nov 6, 2023
D-0236-2022 Class II LOTRIMIN AF (Miconazole nitrate 2%) Deodorant P... Oct 1, 2021
D-0253-2022 Class I Tinactin (Tolnaftate 1%) POWDER SPRAY NET WT 13... Oct 1, 2021
D-0251-2022 Class I Tinactin (Tolnaftate 1%) LIQUID SPRAY NET WT150... Oct 1, 2021
D-0242-2022 Class II Tinactin (Tolnaftate 1%) DEODORANT POWDER SPRAY... Oct 1, 2021

Frequently Asked Questions

cGMP stands for Current Good Manufacturing Practice — the FDA's regulations governing drug manufacturing quality. A cGMP recall means the company failed to follow required manufacturing standards. This could involve inadequate testing, poor environmental controls, documentation failures, or process deviations. cGMP recalls do not always mean the product is directly harmful — in many cases, quality records are insufficient to confirm the product meets specifications. However, the FDA requires a recall because without proper documentation, product quality cannot be assured. These are often Class II or Class III recalls.

Not necessarily. Many drug recalls are initiated because of quality system failures or test results that suggest a product might not meet specifications — even if no patients have reported harm. The FDA uses a precautionary approach: if there is reason to believe quality standards were not met, a recall is required regardless of whether adverse effects have been reported. Class I recalls typically involve a reasonable probability of harm; Class II recalls may cause temporary health issues; Class III recalls are for products unlikely to cause adverse health consequences but that still violate regulations.

Pharmacies typically receive recall notices directly from drug wholesalers and manufacturers within days of the recall being announced. Your pharmacist can look up whether any product in your prescription history matches a recalled lot number. For current recalls, the FDA publishes updates at FDA.gov/safety/recalls-market-withdrawals-safety-alerts and sends MedWatch email alerts for significant drug safety issues. You can sign up for MedWatch alerts at FDA.gov. Most major pharmacy chains also have their own recall notification systems that automatically alert pharmacists when a recalled product is in their inventory.

What Should You Do?

Stop using this medication if affected by this recall. Contact your pharmacist or prescribing doctor immediately for guidance. Do not flush medications — use a drug take-back program.